LIS22
/ Xenothera
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
May 05, 2025
LIS22: AN EFFECTIVE MULTIMODAL POLYCLONAL ANTIBODY TARGETING T-CELL MALIGNANCIES
(ICML 2025)
- "LIS22 efficacy in vivo were evaluated in NMRI nude mice and SRG rats using T1301 and Jurkat cancer cell lines...In both CDC and apoptosis cytotoxicity assays, LIS22 displayed a significantly higher potency on T cell blood cancers and no toxicity on healthy blood cells compared to Alemtuzumab (Anti-CD52) and Belinostat (HDAC inhibitor)... LIS22 has emerged as a novel and promising antibody for the treatment of T-cell hematologic malignancies. It is currently under clinical investigation (Phase I/II) for the treatment of peripheral T-cell lymphoma (PTCL)."
Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma
May 05, 2025
PALT TRIAL: FIRST IN CLASS GLYCO-HUMANIZED POLYCLONAL ANTIBODY DIRECTED AGAINST TUMORAL T CELLS, IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T CELLS LYMPHOMA
(ICML 2025)
- P1/2 | "Background: LIS22 is a first in class glyco-humanized polyclonal antibody (GH-pAb) targeting selectively and simultaneously multiple tumor-associated malignant T-cell antigens... Accrual is ongoing in this first in human trial"
Clinical • Hematological Malignancies • Hepatosplenic T-cell Lymphoma • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma
March 06, 2024
LIS22, a first in class polyclonal antibody immunotherapy in T cell blood cancers
(AACR 2024)
- "LIS22 efficacy in vivo were evaluated in NMRI nude mice and SRG rats using T1301 and Jurkat cancer cell lines...In both CDC and apoptosis cytotoxicity assays, LIS22 displayed a significantly higher potency on T cell blood cancers and no toxicity on healthy blood cells compared to PTCL clinically active drug Alemtuzumab (Anti-CD52)... LIS22 appeared as a novel and promising cancer immunotherapy against T Cell hematologic malignancies. It has already been administered to human in another indication and showed a satisfactory PK and safety profile (no signs of immunotoxicity or systemic cytokine release). LIS22 is now ready to enter Phase I/II in the coming months for the treatment of peripheral T cell lymphoma (PTCL)."
Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma
August 07, 2023
Orphan Designation: Treatment of T-cell lymphoma
(FDA)
- Date Designated: 08/07/2023
Orphan drug • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma
August 09, 2023
Orphan Designation: Treatment of idiopathic pulmonary fibrosis
(FDA)
- Date Designated: 08/09/2023
Orphan drug • Idiopathic Pulmonary Fibrosis • Respiratory Diseases
1 to 5
Of
5
Go to page
1